TradingMenu expanded
Forge Markets Forge Pro Browse Companies
DataMenu expanded
Forge Data Private Market Index Forge Accuidity Index IPO Stock Tracker
SolutionsMenu expanded
For Institutions For Shareholders For Investors For Companies In Europe
InsightsMenu expanded
All Insights Blog Glossary Reports Videos Webinars
Popular Topics
Buying Pre-IPO Shares Selling Pre-IPO Shares Private Market Updates Forge Investment Outlook Startup News Tech IPO Calendar for 2024
AboutMenu expanded
About Us Team Investor Relations People & Culture Careers FAQs
Log In Sign Up
Trading Menu expandedTrading
Forge Markets
Forge Pro
Browse Companies
Data Menu expandedData
Forge Data
Private Market Index
Forge Accuidity Index
IPO Stock Tracker
Solutions Menu expandedSolutions
For Institutions
For Shareholders
For Investors
For Companies
In Europe
Insights Menu expandedInsights
All Insights
Blog
Glossary
Reports
Videos
Webinars
Popular Topics
Buying Pre-IPO Shares
Selling Pre-IPO Shares
Private Market Updates
Forge Investment Outlook
Startup News
Tech IPO Calendar for 2024
About Menu expandedAbout
About Us
Team
Investor Relations
People & Culture
Careers
FAQs
Trading / Browse Private Companies / Prellis Biologics Stock

Prellis Biologics Stock

prellisbio.comHealthcare / BioTech & PharmaFounded: 2016

Prellis Biologics, is a San francisco, California based 3-D printing company specializing in organ and tissue engineering. Prellis Biologics focuses on research and development that aims to provide solutions within the transplatation and donation healthcare industry, through holographic bioprinting. Additionally, Prellis Biologics researches healthcare solutions for cancerous diseases such as tumor, through its proprietary, 3-D technology.

Buy or sell Prellis Biologics stockLearn more about Prellis Biologics IPO

Register To Buy and Sell Shares

For more details on financing and valuation for Prellis Biologics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Prellis Biologics’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Prellis Biologics.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Prellis Biologics investors also invested in these private companies

True Ventures
Khosla Ventures
Celesta Capital
SOSV

Team

Management Team

Mike Nohaile
Chief Executive Officer
Melanie Matheu, PhD
Founder & Chief Technology Officer
kevin Chapman, PhD
Chief Scientific Officer
Yelda Kaya, MBBS, LLC, MBA
Chief Business Officer
Andrew McFarland, PhD
Senior Vice President of Technology
Erin Stephens, PhD
Vice President of Tissue Engineering and Antibody Discovery

Board Members

James Rothman
Cell Biologist
Lei Meng
Advisor
Michael Marks
Celesta Capital

Frequently Asked Questions About Prellis Biologics’ Stock

plusminus
Can you buy Prellis Biologics’ stock?
Prellis Biologics is not publicly traded on NYSE or NASDAQ in the U.S. To buy Prellis Biologics’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell Prellis Biologics’ stock?
Yes, you can sell stock of a private company like Prellis Biologics. Forge can help you sell your Prellis Biologics stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is Prellis Biologics’ stock price?
Prellis Biologics is a privately held company and therefore does not have a public stock price. However, you may access Prellis Biologics’ private market stock price with Forge Data.
plusminus
What is Prellis Biologics’ stock ticker symbol?
Prellis Biologics does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Other companies like Prellis Biologics in the BioTech & Pharma sector

Egenesis

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$387.57MM

Colossal Biosciences

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$1.01B

Prime Medicine

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$1.23B

ADARx Pharmaceuticals

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$827.77MM

Altos Labs

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$6.33B

Tempus

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$8.7B

Pendulum Therapeutics

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$308.05MM

Cytonics

Sector
Healthcare / BioTech & Pharma
 
 

AI Therapeutics

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$110MM

News Highlights

FINSEMS 08/11/2022
Prellis Biologics Raises $35M in Series C Funding
Prellis Biologics, a San Francisco, CA-based biotherapeutics company, raised $35M in Series C funding

Trending Companies

Frequently Asked Questions

Updated on: Apr 24, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.